Advertisement

Picture EBD Group BioPharm America 2018 Boston Speakers 600x60px
Document › Details

Sygnis AG. (2/2/17). "Press Release: Sygnis AG Announces the Launch of TrueHelix". Madrid & Heidelberg.

Organisations Organisation Sygnis AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard)
  Group Genetrix (ES) (Group)
  Organisation 2 MC Services AG
Products Product TrueHelix bioinformatics service platform
  Product 2 TruePure bioinformatics service tool
Persons Person Lanckriet, Heikki (Expedeon 201111 CEO + Founder)
  Person 2 de la Huerta Martinez, Pilar (Sygnis Pharma 201303– CEO + CFO before Genetrix CEO before Zeltia)
     


> TrueHelix establishes SYGNIS as a reference in next generation sequencing (NGS) related bioinformatics

> The TruePure tool addresses sample contamination, a key pitfall in NGS workflows

> SYGNIS reinforces its client focused marketing approach by providing customer support in sequencing analysis


SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced the launch of TrueHelix a new bioinformatics service platform, delivered through a dedicated web portal, for Next Generation Sequencing (NGS) providers and customers to analyze their sequencing data. The service platform strengthens SYGNIS’ position in the NGS user market and facilitates a service approach, which complements and supports SYGNIS’ genomic product range by addressing the key customer needs.

The first service launched on the TrueHelix platform will be TruePure, a bioinformatics tool that validates sample purity and checks for potential sample contamination, which is a key concern in NGS workflows and can originate either from the lab environment or introduced during the sequencing process. Often contamination goes unnoticed resulting in poor quality results and potentially faulty analysis. With the TruePure tool, customers obtain valuable information on the quality of the data and contamination. The TrueHelix platform and tools will be available to all NGS users and will be of particular interest to existing TruePrime users and scientists engaged in Whole Genome sequencing data analysis.

In oncology, like with any other clinical application, confirmation that the amplified sample to be analyzed is free from contamination is vital and adds significant value for the end user. TruePure is the first tool in a range of services that SYGNIS intends to launch in 2017. These services will position SYGNIS as a reference company in the NGS bioinformatics.

Dr. Heikki Lanckriet, Co-CEO and CSO of SYGNIS said: “We are very proud of our new bioinformatics platform supporting NGS users with their data analysis. These users face many challenges when analyzing the raw NGS data and sample contamination is a key concern that hampers accurate data analysis. Our ambition is to support our customers by providing them with added value tools & services that will address the key pitfalls in their workflows whilst showcasing SYGNIS’ expertise and knowledge in NGS bioinformatics.”


For further information, please contact:

SYGNIS AG

Dr. Heikki Lanckriet
Co-CEO/CSO
Phone : +44 1223 873 364
Email: heikki.lanckriet@sygnis.com

Pilar de la Huerta
Co-CEO/CFO
Phone: +34 91 192 36 50
Email: pdelahuerta@sygnis.com

MC Services AG
Raimund Gabriel
Managing Partner
Phone: +49 89 210228 0
Email: raimund.gabriel@mc-services.eu


About SYGNIS AG: www.sygnis.com

SYGNIS AG is specialized in the development and the commercialization of proprietary technologies and offers a wide range of different commercial products addressing key challenges in molecular biology. With the acquisition of Expedeon Holdings, Ltd. based in Cambridge, UK, SYGNIS has added a complementary proteomic product portfolio. Resulting from this significant expansion, SYGNIS’ product portfolio now covers the entire workflow of molecular biology. The products are sold through a direct sales force and several distribution partners in Europe, the US and Asia. SYGNIS AG has offices in Germany, Spain and the UK, production sites in the UK and the US as well as sales offices in Asia. The company is listed on the German Stock Exchange in Frankfurt in the Prime Standard segment (Ticker: LIO1; ISIN: DE000A1RFM03).

### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason.###

Madrid, Spain/Heidelberg, Germany
SYGNIS AG, Waldhofer Str. 104, 69123 Heidelberg, Germany, www.sygnis.de, Tel.: + 49-6221- 3540-125, Fax: +49-6221- 3540-127

   
Record changed: 2017-02-08

Advertisement

Picture [MSC] Mass-Spec-Capital.com – The Mass Spectrometry Web Portal 600x80px

More documents for Genetrix (ES) (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [MSC] Mass-Spec-Capital.com – The Mass Spectrometry Web Portal 600x80px




» top